PDF herunterladen
Homeopathy 2011; 100(04): 237-243
DOI: 10.1016/j.homp.2011.05.006
Original Paper
Copyright © The Faculty of Homeopathy 2011

Different forms of administration of biotherapy 7dH in mice experimentally infected by Trypanosoma cruzi produce different effects

Fabiana Nabarro Ferraz
1   Basic Health Science Department, Universidade Estadual de Maringá, Paraná, Brazil
,
Geysa Karla Simoni
1   Basic Health Science Department, Universidade Estadual de Maringá, Paraná, Brazil
,
Anélio do Nascimento
2   Basic Parasitology Department, Universidade Estadual de Maringá, Paraná, Brazil
,
Carolina Sundin de Melo
1   Basic Health Science Department, Universidade Estadual de Maringá, Paraná, Brazil
,
Denise Lessa Aleixo
1   Basic Health Science Department, Universidade Estadual de Maringá, Paraná, Brazil
,
Mônica Lúcia Gomes
1   Basic Health Science Department, Universidade Estadual de Maringá, Paraná, Brazil
,
Miguel Spack
1   Basic Health Science Department, Universidade Estadual de Maringá, Paraná, Brazil
,
Silvana Marques de Araújo
1   Basic Health Science Department, Universidade Estadual de Maringá, Paraná, Brazil
2   Basic Parasitology Department, Universidade Estadual de Maringá, Paraná, Brazil
› Institutsangaben
Verantwortlicher Herausgeber dieser Rubrik:
Weitere Informationen

Publikationsverlauf

Received07. Februar 2011

accepted11. Mai 2011

Publikationsdatum:
20. Dezember 2017 (online)

    Lizenzen und Reprints

Objective: To evaluate the effects of different forms of administration of the blood trypomastigotes biotherapy 7dH in mice experimentally infected with Trypanosoma cruzi.

Material and methods: Male swiss mice were inoculated with 1400 blood trypomastigotes of the Y strain of T. cruzi and allocated into 5 treatment groups: IC (distilled water); TCBZ (benznidazole); TBA7dH (biotherapy 7dH 20 days after infection); TBB7dH7 (biotherapy 7dH seven days before infection); TBB7dH30 (biotherapy 7dH 30 days before infection). Parasitological parameters assessed included pre-patent and patent periods, parasitemia peak, total parasitemia, mortality and survival rates. Cure index was obtained by fresh blood examination, hemoculture and polymerase chain reaction (PCR).

Results: The TBB7dH7 group showed a reduction in parasitemia peak, parasitemia area under the curve and total parasitemia. TBB7dH30 showed a tendency to increased pre-patent and survival periods, peak parasitemia was increased without increased total parasitemia. TBA7dH did not present significant alterations in the parasitological parameters analyzed.

Conclusions: Biotherapy 7dH given before infection (7 or 30 days) produces different effects suggesting modulation of the host’s immune system. The effects range from reduced parasitemia to its effective increase. The use of biotherapy to treat T. cruzi infection including dose, potency and schedule deserves further investigation.

Keywords

Trypanosoma cruzi - Nosode - Chagas disease - Homeopathy - Biotherapy
 

  • References

  • 1 WHO (World Health Organization). New global effort to eliminate Chagas disease. Wkly Epidemiol Rec 2007; 82 (28/29) 259-260.
    PubMedGoogle Scholar
  • 2 Castro S. The challenge of Chagas disease chemotherapy: an update on drugs assayed against Trypanosoma cruzi . Acta Trop 1993; 53 (02) 83-98.
    CrossrefPubMedGoogle Scholar
  • 3 Fabbro D.L., Streiger M.L., Arias E.D., Bizai M.L., Barco M., Amicone N.A. Trypanocide treatment among adults with chronic Chagas disease living in Santa Fe city (Argentina), over a mean follow-up of 21 years: parasitological, serological and clinical evolution. Rev Soc Bras de Med Trop 2007; 40 (01) 1-10.
    PubMedGoogle Scholar
  • 4 Ferraz M.L., Gazzinelli R.T., Alves R.O., Urbina J.A., Romanha A.J. The anti-Trypanosoma cruzi activity of posaconazole in a murine model of acute Chagas disease is less dependent on gamma interferon than that of benznidazole. Antimicrob Agents Chemother 2007; 51 (04) 1359-1364.
    CrossrefPubMedGoogle Scholar
  • 5 Sanz-Rodríguez C.E., Concepción J.L., Pekerar S., Oldfield E., Urbina J.A. Bisphosphonates as inhibitors of Trypanosoma cruzi hexokinase: kinetic and metabolic studies. J Biol Chem 2007; 282 (17) 12377-12387.
    CrossrefPubMedGoogle Scholar
  • 6 Almeida R.L., Campos M.C.O., Herrera L.V.B., Bonamin L.V., Fonseca A.H. Effects of homeopathy in mice experimentally infected with Trypanosoma cruzi . Homeopathy 2008; 97 (02) 65-69.
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 7 Queiroz A.O., Xavier S.C.C., Faria K.G., Bernardo R.R., Leitão T.C.A. Avaliação do bioterápico Trypanosoma cruzi 30 DH: Um Estudo in vivo . Cult Homeopát 2006; 17: 9-13.
    PubMedGoogle Scholar
  • 8 Holandino C. Chagas disease: an old disease in need of new therapies. Homeopathy 2008; 97 (02) 57-58.
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 9 Aleixo D.L., Ferraz F.N., De Melo C.S. et al. Changes of RAPD profile of Trypanosoma cruzi II with Canova and Benznidazole. Homeopathy 2008; 97 (02) 59-64.
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 10 Brasil Ministério da Saúde. Gabinete do Ministro. Portaria n° 971, de 03 de maio de 2006. Diário Oficial da União, Brasília (DF) 2006 4 maio; seção 1 (84) 20-25.
    PubMedGoogle Scholar
  • 11 Organización Mundial de la Salud. Estrategia de la OMS sobre medicina tradicional 2002–2005. Ginebra: Organización Mundial de la Salud; 2002. pp 65.
    Google Scholar
  • 12 Sarembaud A. Homeopatia – Conceitos Básicos. 2a edn. São Paulo: Andrei; 2003. pp 309.
    Google Scholar
  • 13 Bellavite P., Ortolani R., Confort A., Piasere V. Immunology and homeopathy. Historical background. eCAM 2005; 2 (04) 414-452.
    PubMedGoogle Scholar
  • 14 Farmacopéia Homeopática Brasileira: Parte I – Métodos Gerais. 2a edn. São Paulo: Atheneu; 1997.
    Google Scholar
  • 15 Danninger T., Gallenberger K., Kraeling J. Immunologic changes in healthy probands and HIV infected patients after oral administration of Staphylococcus aureus 12C: a pilot study. Br Hom J 2000; 89 (03) 106-115.
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 16 Silva A.M.C.P., Schwartz F.F., Cardoso M.V., César A.T., Sollero P.A. Uso de bioterápico de Mycoplasma spp. em rebanho bovino leiteiro. Cult Homeopát 2005; 4 (13) 43-47.
    PubMedGoogle Scholar
  • 17 Bellavite P., Ortolani R., Pontarollo F., Piasere V., Benato G., Conforti A. Immunology and homeopathy. Clinical studies—part 1. eCAM 2006; 3 (02) 171-186.
    PubMedGoogle Scholar
  • 18 Araújo-Jorge T.C. Camundongo. In: Araújo-Jorge T.C., Castro S.L. Doença de Chagas: Manual para experimentação animal. 1a edn. 2000. Rio de Janeiro: Editora Fio Cruz; 134-140.
    Google Scholar
  • 19 Silva L.H.P., Nussenweig V. Sobre uma cepa de Trypanosoma cruzi altamente virulenta para camundongo branco. Folia Clín Biol 1953; 20: 191-207.
    PubMedGoogle Scholar
  • 20 Fernandes O., Campbell D.A. Trypanosoma cruzi cepas de Eleição. In: Araújo-Jorge T.C., Castro S.L. Doença de Chagas: Manual para experimentação animal. 1a edn. 2000. Rio de Janeiro: Editora Fio Cruz; 178-181.
    Google Scholar
  • 21 Brener Z. Therapeutic activity and criterion of cure on mice experimentally infected with Trypanosoma cruzi . Rev Inst Med Trop Sao Paulo 1962; 4: 389-396.
    PubMedGoogle Scholar
  • 22 Filardi L.S., Brener Z. Susceptibility and natural resistance of Trypanosoma cruzi strains to drugs used clinically in Chagas disease. Trans R Soc of Trop Med Hyg 1987; 81 (05) 755-759.
    PubMedGoogle Scholar
  • 23 Avila H., Sigman D., Cohen L., Millikan R., Simpson L. Polymerase chain reaction of Trypanosoma cruzi kinetoplast minicircle DNA isolated from whole blood lysate: diagnosis of chronic Chagas disease. Mol Biochem Parasitol 1991; 48 (02) 211-222.
    CrossrefPubMedGoogle Scholar
  • 24 Wincker P., Britt C., Pereira J.B., Cardoso M.A., Oelemann W., Morel C.M. Use of a simplified polymerase chain reaction procedure to detect Trypanosoma cruzi in blood samples patients in a rural endemic area. Am J Trop Med Hyg 1994; 51 (06) 771-777.
    CrossrefPubMedGoogle Scholar
  • 25 Gomes M.L., Macedo A.M., Pena S.D.J., Chiari E. Genetic relationships between Trypanosoma cruzi strains isolated from chronic patients in southern Brazil as revealed by RAPD and SSR-PCR analysis. Acta Trop 1998; 69 (02) 99-109.
    CrossrefPubMedGoogle Scholar
  • 26 Gomes M.L., Macedo A.M., Vago R., Pena S.D.J., Galvão L.M.C., Chiari E. Trypanosoma cruzi: optimization of polymerase chain reaction for detection in human blood. Exp Parasitol 1998; 88 (01) 28-33.
    CrossrefPubMedGoogle Scholar
  • 27 Santos F.R., Pena S.D.J., Epplen J.T. Genetic and population study of a Y-linked tetranucleotide repeat DNA polymorphism with a simple non-isotopic technique. Hum Genet 1993; 90 (06) 655-656.
    PubMedGoogle Scholar
  • 28 Brener Z., Andrade Z.A., Netto M.B. Trypanosoma cruzi e doença de Chagas. 2a edn. Rio de Janeiro: Guanabara Koogan; 2000. pp 431.
    Google Scholar
  • 29 Lyrio C. Nosódios (Bioterápico): Repertório, 1a edn, Rio de Janeiro 2002, pp 22.
    PubMed
  • 30 Basombrio M.A., Besuschio S. Trypanosoma cruzi culture used as vaccine to prevent chronic Chagas disease in mice. Infect Immun 1982; 36 (01) 351-356.
    PubMedGoogle Scholar
  • 31 Sepulveda P., Hontebeyrie M., Liegeard P., Mascilli A., Norris K.A. DNA-based immunization with Trypanosoma cruzi complement regulatory protein elicits complement lytic antibodies and confers protection against Trypanosoma cruzi infection. Infect Immun 2000; 68 (09) 4986-4991.
    CrossrefPubMedGoogle Scholar
  • 32 Bastide M., Lagache A., Lemaire-Misonne C. Le paradigme des signifiants: schème d’information applicable à l’Immunologie et à l’Homáopathie. Rev Int Systémique 1995; 9: 237-249.
    PubMedGoogle Scholar
  • 33 Costa B, Siqueira C, Veiga V, Soares R, Holandino C. Alterações celulares induzidas pelo bioterápico Candida albicans 30dH: um estudo in vitro. CD room do XXIX Congresso Brasileiro de Homeopatia, São Paulo, 2008.
    PubMed
  • 34 Smit E., Pretorius E., Anderson R., Oommen J., Potjo M. Differentiation of human monocytes in vitro following exposure to Canova in the absence of cytokines. Ultrastruct Pathol 2008; 32 (04) 147-152.
    CrossrefPubMedGoogle Scholar
  • 35 Soignet S.L., Maslak P., Wang Z.G. et al. Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide. N Engl J Med 1998; 339 (19) 1341-1348.
    CrossrefPubMedGoogle Scholar
  • 36 Jonas WB, Gaddipati JP, Rajeshkumar NV, et al. In vitro and in vivo assessment of homeopathic treatment for prostate cancer. Paper presented at: Society of Integrative Oncology First International Conference. New York, NY, 2004.
    PubMed
  • 37 Olivieri B.P., Farias-De-Oliveira D.A., Araujo-Jorge T.C., Cotta-de-Almeida V. Benznidazole therapy in Trypanosoma cruzi-infected mice blocks thymic involution and apoptosis of CD4+CD8+ double-positive thymocytes. Antimicrob Agents Chemother 2005; 49 (05) 1981-1987.
    CrossrefPubMedGoogle Scholar
  • 38 Sandri PF. Efeitos do bioterápico 17dH na infecção pelo Trypanosoma cruzi em camundongos de diferentes idades. Dissertação de Mestrado, Programa de pós-graduação em Biociências Aplicadas à Farmácia, Universidade Estadual de Maringá, Maringá, 2010, 70 pp.
    PubMed
  • 39 Carillo R.J. O milagre da imperfeição – Vida, Saúde e Doença numa visão sistêmica. 1a edn. São Paulo: Editora Cultrix; 2008. pp 167.
    Google Scholar
  • 40 Hahnemann S. Organon da arte de curar. 6a edn. São Paulo: Robe Editorial; 2001. pp 248.
    Google Scholar
  • 41 Moffett J.R., Arun P., Namboodiri M.A.A. Laboratory research in homeopathy: con. Integr Cancer 2006; 5 (04) 333-342.
    PubMedGoogle Scholar
  • 42 Miyamoto C.T., Gomes M.L., Marangon A.V. et al. Trypanosoma cruzi: sensitivity of the polymerase chain reaction for detecting the parasite in the blood of mice infected with different clonal genotypes. Exp Parasitol 2006; 112 (03) 198-201.
    CrossrefPubMedGoogle Scholar
  • 43 Bonamin L.V. Dados Experimentais que fundamentam teorias interpretativas sobre ultradiluições – Tributo a Madaleine Bastide. Cult Homeopát 2007; 21: 29-32.
    PubMedGoogle Scholar